---
layout: default
title: ModalSurv: Investigating opportunities and limitations of multimodal deep survival learning in prostate and bladder cancer
---

# ModalSurv: Investigating opportunities and limitations of multimodal deep survival learning in prostate and bladder cancer

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2509.05037" class="toolbar-btn" target="_blank">ğŸ“„ arXiv: 2509.05037v4</a>
  <a href="https://arxiv.org/pdf/2509.05037.pdf" class="toolbar-btn" target="_blank">ğŸ“¥ PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2509.05037v4" data-paper-url="__CURRENT_PAGE__" onclick="toggleFavorite(this, '2509.05037v4', 'ModalSurv: Investigating opportunities and limitations of multimodal deep survival learning in prostate and bladder cancer')" title="æ·»åŠ åˆ°æ”¶è—å¤¹">â˜† æ”¶è—</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">ğŸ”— åˆ†äº«</button>
</div>


**ä½œè€…**: Noorul Wahab, Ethar Alzaid, Jiaqi Lv, Fayyaz Minhas, Adam Shephard, Shan E Ahmed Raza

**åˆ†ç±»**: cs.LG

**å‘å¸ƒæ—¥æœŸ**: 2025-09-05 (æ›´æ–°: 2025-12-10)

**å¤‡æ³¨**: 4 pages, 1 figure, 2 tables

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

**ModalSurvï¼šå¤šæ¨¡æ€æ·±åº¦ç”Ÿå­˜å­¦ä¹ åœ¨å‰åˆ—è…ºç™Œå’Œè†€èƒ±ç™Œä¸­çš„åº”ç”¨ä¸å±€é™æ€§ç ”ç©¶**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **æ”¯æŸ±ä¹ï¼šå…·èº«å¤§æ¨¡å‹ (Embodied Foundation Models)**

**å…³é”®è¯**: `å¤šæ¨¡æ€å­¦ä¹ ` `ç”Ÿå­˜åˆ†æ` `æ·±åº¦å­¦ä¹ ` `ç™Œç—‡é¢„å` `äº¤å‰æ³¨æ„åŠ›`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. ç™Œç—‡çš„ä¸ªä½“åŒ–æ²»ç–—éœ€è¦å‡†ç¡®çš„ç”Ÿå­˜é¢„æµ‹ï¼Œè€Œç°æœ‰æ–¹æ³•åœ¨å¤šæ¨¡æ€æ•°æ®èåˆæ–¹é¢å­˜åœ¨æŒ‘æˆ˜ã€‚
2. ModalSurvé€šè¿‡æ¨¡æ€ç‰¹å®šæŠ•å½±å’Œäº¤å‰æ³¨æ„åŠ›èåˆï¼Œæ•´åˆä¸´åºŠã€å½±åƒã€ç—…ç†å’ŒåŸºå› æ•°æ®è¿›è¡Œç”Ÿå­˜é¢„æµ‹ã€‚
3. å®éªŒè¡¨æ˜ï¼Œå¤šæ¨¡æ€æ¨¡å‹åœ¨ç‰¹å®šæ•°æ®é›†ä¸Šè¡¨ç°è‰¯å¥½ï¼Œä½†åœ¨å¤–éƒ¨æµ‹è¯•ä¸­ä¸å¦‚ä»…ä½¿ç”¨ä¸´åºŠç‰¹å¾çš„æ¨¡å‹ï¼Œæ­ç¤ºäº†æ³›åŒ–æ€§é—®é¢˜ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

æœ¬æ–‡æå‡ºäº†ModalSurvï¼Œä¸€ä¸ªå¤šæ¨¡æ€æ·±åº¦ç”Ÿå­˜å­¦ä¹ æ¡†æ¶ï¼Œæ—¨åœ¨æ•´åˆä¸´åºŠæ•°æ®ã€MRIå½±åƒã€ç»„ç»‡ç—…ç†å­¦å’ŒRNAæµ‹åºæ•°æ®ï¼Œé€šè¿‡æ¨¡æ€ç‰¹å®šçš„æŠ•å½±å’Œäº¤å‰æ³¨æ„åŠ›èåˆè¿›è¡Œç™Œç—‡ç”Ÿå­˜é¢„æµ‹ã€‚åœ¨CHIMERA Grand Challengeæ•°æ®é›†ä¸Šï¼ŒModalSurvåœ¨å‰åˆ—è…ºç™Œé¢„æµ‹ä¸­å–å¾—äº†0.7402çš„C-indexï¼ˆæ’åç¬¬ä¸€ï¼‰ï¼Œåœ¨è†€èƒ±ç™Œé¢„æµ‹ä¸­å–å¾—äº†0.5740çš„C-indexï¼ˆæ’åç¬¬äº”ï¼‰ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œåœ¨å¤–éƒ¨æµ‹è¯•ä¸­ï¼Œä»…ä½¿ç”¨ä¸´åºŠç‰¹å¾çš„æ¨¡å‹è¡¨ç°ä¼˜äºå¤šæ¨¡æ€æ¨¡å‹ï¼Œçªæ˜¾äº†å¤šæ¨¡æ€æ•°æ®å¯¹é½æœ‰é™å’Œæ½œåœ¨è¿‡æ‹Ÿåˆçš„æŒ‘æˆ˜ã€‚å±€éƒ¨éªŒè¯æ˜¾ç¤ºäº†å¤šæ¨¡æ€çš„å¢ç›Šï¼Œä½†æ³›åŒ–èƒ½åŠ›æœ‰é™ã€‚ModalSurvç³»ç»Ÿåœ°è¯„ä¼°äº†å¤šæ¨¡æ€ç”Ÿå­˜å»ºæ¨¡ï¼Œå¼ºè°ƒäº†å…¶åœ¨å¯æ‰©å±•ã€å¯æ³›åŒ–çš„ç™Œç—‡é¢„åæ–¹é¢çš„æ½œåŠ›å’Œå½“å‰å±€é™æ€§ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šè®ºæ–‡æ—¨åœ¨è§£å†³ç™Œç—‡ç”Ÿå­˜é¢„æµ‹é—®é¢˜ï¼Œç°æœ‰æ–¹æ³•åœ¨æ•´åˆå¤šç§æ¨¡æ€æ•°æ®ï¼ˆä¸´åºŠã€å½±åƒã€ç—…ç†ã€åŸºå› ï¼‰æ—¶é¢ä¸´æŒ‘æˆ˜ï¼Œä¾‹å¦‚æ•°æ®å¯¹é½å›°éš¾ã€ä¿¡æ¯å†—ä½™ä»¥åŠæ¨¡å‹æ³›åŒ–èƒ½åŠ›ä¸è¶³ç­‰é—®é¢˜ã€‚è¿™äº›ç—›ç‚¹é™åˆ¶äº†å¤šæ¨¡æ€æ•°æ®åœ¨ç™Œç—‡é¢„åä¸­çš„åº”ç”¨ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡çš„æ ¸å¿ƒæ€è·¯æ˜¯è®¾è®¡ä¸€ä¸ªå¤šæ¨¡æ€æ·±åº¦å­¦ä¹ æ¡†æ¶ï¼Œé€šè¿‡æ¨¡æ€ç‰¹å®šçš„æŠ•å½±å±‚æå–å„æ¨¡æ€çš„ç‰¹å¾ï¼Œå¹¶åˆ©ç”¨äº¤å‰æ³¨æ„åŠ›æœºåˆ¶å®ç°æ¨¡æ€é—´çš„æœ‰æ•ˆèåˆã€‚è¿™ç§è®¾è®¡æ—¨åœ¨å…‹æœæ•°æ®å¼‚æ„æ€§å¸¦æ¥çš„æŒ‘æˆ˜ï¼Œå……åˆ†åˆ©ç”¨ä¸åŒæ¨¡æ€çš„ä¿¡æ¯äº’è¡¥æ€§ï¼Œä»è€Œæé«˜ç”Ÿå­˜é¢„æµ‹çš„å‡†ç¡®æ€§ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šModalSurvæ¡†æ¶åŒ…å«ä»¥ä¸‹ä¸»è¦æ¨¡å—ï¼š1) æ¨¡æ€ç‰¹å®šæŠ•å½±å±‚ï¼šå°†ä¸åŒæ¨¡æ€çš„æ•°æ®æ˜ å°„åˆ°ç»Ÿä¸€çš„ç‰¹å¾ç©ºé—´ã€‚2) äº¤å‰æ³¨æ„åŠ›èåˆå±‚ï¼šåˆ©ç”¨æ³¨æ„åŠ›æœºåˆ¶å­¦ä¹ ä¸åŒæ¨¡æ€ä¹‹é—´çš„å…³è”æ€§ï¼Œå®ç°ä¿¡æ¯èåˆã€‚3) ç”Ÿå­˜é¢„æµ‹å±‚ï¼šåŸºäºèåˆåçš„ç‰¹å¾è¿›è¡Œç”Ÿå­˜æ¦‚ç‡é¢„æµ‹ã€‚æ•´ä½“æµç¨‹æ˜¯å…ˆå¯¹å„æ¨¡æ€æ•°æ®è¿›è¡Œé¢„å¤„ç†å’Œç‰¹å¾æå–ï¼Œç„¶åé€šè¿‡äº¤å‰æ³¨æ„åŠ›è¿›è¡Œèåˆï¼Œæœ€ååˆ©ç”¨ç”Ÿå­˜é¢„æµ‹æ¨¡å‹è¾“å‡ºé¢„æµ‹ç»“æœã€‚

**å…³é”®åˆ›æ–°**ï¼šè¯¥è®ºæ–‡çš„å…³é”®åˆ›æ–°åœ¨äºæå‡ºäº†ä¸€ä¸ªåŸºäºäº¤å‰æ³¨æ„åŠ›çš„å¤šæ¨¡æ€èåˆæ–¹æ³•ï¼Œèƒ½å¤Ÿè‡ªé€‚åº”åœ°å­¦ä¹ ä¸åŒæ¨¡æ€ä¹‹é—´çš„æƒé‡ï¼Œä»è€Œæ›´æœ‰æ•ˆåœ°åˆ©ç”¨å¤šæ¨¡æ€ä¿¡æ¯ã€‚ä¸ä¼ ç»Ÿçš„ç®€å•æ‹¼æ¥æˆ–åŠ æƒå¹³å‡æ–¹æ³•ç›¸æ¯”ï¼Œäº¤å‰æ³¨æ„åŠ›æœºåˆ¶èƒ½å¤Ÿæ›´å¥½åœ°æ•æ‰æ¨¡æ€é—´çš„å¤æ‚å…³ç³»ï¼Œæé«˜æ¨¡å‹çš„é¢„æµ‹æ€§èƒ½ã€‚

**å…³é”®è®¾è®¡**ï¼šåœ¨æ¨¡æ€ç‰¹å®šæŠ•å½±å±‚ï¼Œè®ºæ–‡å¯èƒ½ä½¿ç”¨äº†ä¸åŒçš„ç¥ç»ç½‘ç»œç»“æ„ï¼ˆå¦‚å·ç§¯ç¥ç»ç½‘ç»œã€å¾ªç¯ç¥ç»ç½‘ç»œç­‰ï¼‰æ¥é€‚åº”ä¸åŒæ¨¡æ€æ•°æ®çš„ç‰¹ç‚¹ã€‚äº¤å‰æ³¨æ„åŠ›èåˆå±‚å¯èƒ½é‡‡ç”¨äº†å¤šå¤´æ³¨æ„åŠ›æœºåˆ¶ï¼Œä»¥æ•æ‰ä¸åŒè§’åº¦çš„æ¨¡æ€é—´å…³ç³»ã€‚ç”Ÿå­˜é¢„æµ‹å±‚é€šå¸¸ä½¿ç”¨Coxæ¯”ä¾‹é£é™©æ¨¡å‹æˆ–ç±»ä¼¼çš„ç”Ÿå­˜åˆ†ææ¨¡å‹ï¼Œå¹¶é‡‡ç”¨è´Ÿå¯¹æ•°ä¼¼ç„¶æŸå¤±å‡½æ•°è¿›è¡Œè®­ç»ƒã€‚å…·ä½“çš„å‚æ•°è®¾ç½®å’Œç½‘ç»œç»“æ„éœ€è¦åœ¨è®ºæ–‡ä¸­è¿›ä¸€æ­¥æŸ¥æ‰¾ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

ModalSurvåœ¨å‰åˆ—è…ºç™Œçš„CHIMERA Grand Challengeæ•°æ®é›†ä¸Šå–å¾—äº†0.7402çš„C-indexï¼Œæ’åç¬¬ä¸€ã€‚è™½ç„¶åœ¨è†€èƒ±ç™Œæ•°æ®é›†ä¸Šæ’åç¬¬äº”ï¼ˆC-indexä¸º0.5740ï¼‰ï¼Œä½†ç ”ç©¶æ­ç¤ºäº†å¤šæ¨¡æ€æ¨¡å‹åœ¨å¤–éƒ¨æµ‹è¯•ä¸­å¯èƒ½ä¸å¦‚ä»…ä½¿ç”¨ä¸´åºŠç‰¹å¾çš„æ¨¡å‹ï¼Œå¼ºè°ƒäº†æ•°æ®æ³›åŒ–æ€§çš„é‡è¦æ€§ã€‚å±€éƒ¨éªŒè¯æ˜¾ç¤ºå¤šæ¨¡æ€èåˆçš„å¢ç›Šï¼Œä½†æ•´ä½“ç»“æœè¡¨æ˜å¤šæ¨¡æ€ç”Ÿå­˜å»ºæ¨¡ä»é¢ä¸´æŒ‘æˆ˜ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

ModalSurvçš„ç ”ç©¶æˆæœå¯åº”ç”¨äºç™Œç—‡çš„ä¸ªä½“åŒ–æ²»ç–—ï¼Œå¸®åŠ©åŒ»ç”Ÿæ›´å‡†ç¡®åœ°é¢„æµ‹æ‚£è€…çš„ç”Ÿå­˜æœŸï¼Œä»è€Œåˆ¶å®šæ›´åˆé€‚çš„æ²»ç–—æ–¹æ¡ˆã€‚è¯¥ç ”ç©¶ä¹Ÿä¸ºå¤šæ¨¡æ€æ•°æ®èåˆåœ¨åŒ»å­¦é¢†åŸŸçš„åº”ç”¨æä¾›äº†å‚è€ƒï¼Œæœ‰åŠ©äºæ¨åŠ¨ç²¾å‡†åŒ»ç–—çš„å‘å±•ã€‚æœªæ¥ï¼Œè¯¥æ–¹æ³•å¯ä»¥æ‰©å±•åˆ°å…¶ä»–ç™Œç—‡ç±»å‹æˆ–å…¶ä»–ç–¾ç—…çš„é¢„åé¢„æµ‹ä¸­ã€‚

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> Accurate survival prediction is essential for personalised cancer treatment. We propose ModalSurv, a multimodal deep survival framework integrating clinical, MRI, histopathology, and RNA-sequencing data via modality-specific projections and cross-attention fusion. On the CHIMERA Grand Challenge datasets, ModalSurv achieved a C-index of 0.7402 (1st) for prostate and 0.5740 (5th) for bladder cancer. Notably, clinical features alone outperformed multimodal models on external tests, highlighting challenges of limited multimodal alignment and potential overfitting. Local validation showed multimodal gains but limited generalisation. ModalSurv provides a systematic evaluation of multimodal survival modelling, underscoring both its promise and current limitations for scalable, generalisable cancer prognosis.

